Physician profile
Lesley M Plotke
NPI 1629207493
$3,227.80
in general payments reported to CMS, 2019-2025
29 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.00 · 2020: $83.33 · 2021: $106 · 2022: $130 · 2023: $574 · 2024: $931 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,829.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $404.22 | 2020-2025 | |
| Abbvie INC. | $395.86 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $351.54 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $288.63 | 2020-2025 | Nemluvio |
| Incyte Corporation | $264.98 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $189.61 | 2022-2025 | Absorica Ld, Winlevi |
| Lilly USA, LLC | $156.68 | 2024-2025 | Taltz, Olumiant, Zepbound |
| Novartis Pharmaceuticals Corporation | $136.55 | 2024-2025 | |
| Amgen INC. | $122.86 | 2023-2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $88.45 | 2023-2024 | Sotyktu |
| Janssen Biotech, INC. | $83.78 | 2023-2025 | Tremfya |
| Leo Pharma INC. | $80.13 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $79.20 | 2022-2025 | Dupixent, Libtayo |
| Mimedx Group, INC. | $64.87 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.98 | 2023-2024 | Spevigo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $53.48 | 2021-2022 | |
| Biofrontera INC. | $52.47 | 2025 | |
| Organon LLC | $52.35 | 2025 | Vtama |
| Almirall LLC | $50.77 | 2021-2024 | Klisyri |
| Verrica Pharmaceuticals INC. | $40.13 | 2024-2025 | Ycanth |
| Dermavant Sciences, INC. | $30.58 | 2024 | Vtama |
| Allergan, INC. | $29.49 | 2020 | |
| Organogenesis INC. | $27.58 | 2025 | Puraply Wound Matrix |
| Sandoz INC. | $24.99 | 2024 | Hyrimoz |
| Dermira, INC. | $24.84 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.87 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.75 | 2023 | Jublia, Duobrii, Arazlo |
| Mayne Pharma Commercial LLC | $18.77 | 2019 | |
| Botanix Sb INC | $17.39 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Plotke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.